QLGN / Qualigen Therapeutics, Inc. - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2025 Qualigen Therapeu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2025 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commis

Qualigen Therapeutics, Inc.

Exhibit 99.1 Qualigen Therapeutics, Inc. Unaudited Pro Forma Balance Sheet As of June 30, 2025 (Giving Effect to the June 2025 Private Placement and the Amended Note) For The Period Ended June 30, 2025 Pro Forma As Reported Preferred Stock A-3 As Adjusted ASSETS Current assets Cash and cash equivalents $ 331,601 $ 4,257,937 $ 4,589,538 Prepaid expenses and other current assets 316,576 — 316,576 Sh

AMENDED AND RESTATED SECURED DEMAND PROMISSORY NOTE

Exhibit 10.1 AMENDED AND RESTATED SECURED DEMAND PROMISSORY NOTE $4,451,462.18 August 21, 2025 FOR VALUE RECEIVED, Marizyme, Inc., a Nevada corporation (the “Marizyme”), “Borrower”), promise to pay to the order of Qualigen Therapeutics, Inc., a Delaware corporation (together with its successors and assigns, “Lender”), on demand, the principal sum of Four Million Four Hundred Fifty One Thousand, Fo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Qualigen Therapeutics, Inc. (Exact name of registrant a

Registration Rights Agreement, dated July 28, 2025, by and among Qualigen Therapeutics, Inc. and the investors named therein.

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”), dated as of July 28, 2025 is by and among each person named on the signature page hereto (each, an “Investor” and collectively, the “Investors”), and Qualigen Therapeutics, Inc., a Delaware corporation (the “Company”). RECITALS WHEREAS, the Company and the Investors have entered into that certain Secu

Regulation FD Disclosure, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2025 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commissi

Qualigen Therapeutics Provides Update on Nasdaq Communications and Continued Listing Status

Exhibit 99.1 Qualigen Therapeutics Provides Update on Nasdaq Communications and Continued Listing Status CARLSBAD, Calif., July 28, 2025 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) received two different communications from the staff of the Nasdaq Listing Qualifications office of the Nasdaq Stock Market, LLC. The Company received the first notice from the Nasdaq L

Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock

Exhibit 99.1 Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock Carlsbad, CA, July 28, 2025 (GLOBE NEWSWIRE) – Qualigen Therapeutics, Inc. (NASDAQ:QLGN) (“Qualigen” or the “Company”), a life sciences company focused on developing platform treatments for adult and pediatric cancers with the potential for orphan drug designations, today announced

Second Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series A-3 Preferred Stock, as filed with the Secretary of State of the State of Delaware on July 28, 2025.

Exhibit 3.1 QUALIGEN THERAPEUTICS, INC. SECOND AMENDED AND RESTATED CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A-3 PREFERRED STOCK PURSUANT TO SECTION 151 OF THE Delaware GENERAL CORPORATION LAW The undersigned, Campbell Becher and Kevin Richardson II, do hereby certify that: 1. They are the President and Secretary, respectively, of Qualigen Therapeutics, Inc., a D

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2025 Qualigen Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2025 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commissi

Qualigen Therapeutics, Inc.

Exhibit 99.2 Qualigen Therapeutics, Inc. Unaudited Pro Forma Balance Sheet As of March 31, 2025 (Giving Effect to the July 2025 Private Placement of Series A-3 Preferred Stock) For The Period Ended March 31, 2025 Preferred Stock Pro Forma As Reported A-3 As Adjusted ASSETS Current assets Cash and cash equivalents $ 30,210 $ 4,257,938 $ 4,288,148 Prepaid expenses and other current assets 565,765 —

Securities Purchase Agreement, dated July 28, 2025, by and among Qualigen Therapeutics, Inc. and the investors named therein.

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 28, 2025, between Qualigen Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS WHEREAS, subject to the terms a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Qualigen Therapeutics, Inc. (Exact name of registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2025 Qualigen Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2025 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commissi

Qualigen Granted New Patents Covering 25 Countries

Exhibit 99.1 Qualigen Granted New Patents Covering 25 Countries CARLSBAD, Calif., July 16, 2025 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company” or “Qualigen”) is announcing an update on patents granted in the first six months of 2025. The patent is Titled “Substitued Naphthalene Diimides and Their Use.” The patent is for the drug, which was developed by Professor Steph

Subsidiaries of the Registrant

Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT None.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended: December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-37428 Qualigen Therapeutics, Inc. (Exact Name of Small Business Issuer

Insider Trading Policy

Exhibit 19.1 INSIDER TRADING POLICY QUALIGEN THERAPEUTICS, INC. Insider Trading Policy Qualigen Therapeutics, Inc. Statement of Policies and Procedures Governing the Prevention of Insider Trading I. Purpose The purchase or sale of securities while possessing material nonpublic (“inside”) information or the disclosure of inside information (“tipping”) to others who may trade in such securities is s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2025 Qualigen Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2025 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commissi

Regulation FD Disclosure, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2025 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commissio

Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q

Exhibit 99.1 Qualigen Therapeutics, Inc. receives expected notification of deficiency from Nasdaq related to delayed filing of quarterly report on Form 10-Q CARLSBAD, Calif., May 19, 2025 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2025 Qualigen Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2025 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commiss

Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K

Exhibit 99.1 Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K CARLSBAD, Calif., May 1, 2025 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended:December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Per

Qualigen to participate in next funding round for NanoSynex

Exhibit 99.1 Qualigen to participate in next funding round for NanoSynex Market size expected to reach $4.7 billion in 2027 CARLSBAD, Calif., January 28, 2025 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”)announced today they will be the first investors participating in the 2025 bridge round of funding for NanoSynex. NanoSynex will be raising up to $500,000. “We are

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2025 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commi

Amended and Restated Certificate of Designation of Series A-2 Preferred Stock filed with the Secretary of State of Nevada on December 23, 2024.

Exhibit 3.2 QUALIGEN THERAPEUTICS, INC. AMENDED AND RESTATED CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A-2 PREFERRED STOCK PURSUANT TO SECTION 151 OF THE Delaware GENERAL CORPORATION LAW The undersigned, Campbell Becher and Kevin Richardson II, do hereby certify that: 1. They are the President and Secretary, respectively, of Qualigen Therapeutics, Inc., a Delaware

Material Modification to Rights of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2024 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Comm

Qualigen Therapeutics, Inc. 5857 Owens Avenue, Suite 300 Carlsbad, California 92008 December 17, 2024

Qualigen Therapeutics, Inc. 5857 Owens Avenue, Suite 300 Carlsbad, California 92008 December 17, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Tylor Howes Re: Qualigen Therapeutics, Inc. Registration Statement on Form S-1 File 33-283708 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 193

As filed with the Securities and Exchange Commission on December 9, 2024.

As filed with the Securities and Exchange Commission on December 9, 2024. Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Qualigen Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 26-3474527 (State or Other Jurisdiction of Incorporation or Organization) (

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table FORM S-1 (Form Type) Qualigen Therapeutics, Inc.

Registration Right Agreement dated November 18, 2024, between Qualigen Therapeutics, Inc. and Certain Investors thereto.

Exhibit 3.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”), dated as of November 18, 2024 is by and among each person named on the signature page hereto (each, an “Investor” and collectively, the “Investors”), and Qualigen Therapeutics, Inc., a Delaware corporation(the “Company”). RECITALS WHEREAS, the Company and the Investors have entered into that certain Se

Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2024 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Comm

Securities Purchase Agreement dated November 18, 2024, between Qualigen Therapeutics, Inc. and Certain Investors thereto.

Exhibit 3.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 18, 2024 between Qualigen Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS WHEREAS, subject to the terms

Director Agreement dated November 21, 2024 between the Company and Graydon Bensler

Exhibit 10.1 QUALIGEN THERAPEUTICS, INC. BOARD OF DIRECTORS AGREEMENT This BOARD OF DIRECTORS AGREEMENT (“Agreement”) by and between QUALIGEN THERAPEUTICS, INC., a Delaware corporation (the “Company”), and the undersigned signatory (the “Director”), provides for director services and shall become effective on November 7, 2024 (the “Effective Date”), according to the following terms and conditions:

Exchange Agreement dated November 18, 2024, between Qualigen Therapcutics. Inc. and Yi Hua Chen.

Exhibit 3.4 EXCHANGE AGREEMENT THIS EXCHANGE AGREEMENT (the “Agreement”), dated as of November 18, 2024, is made by and between Qualigen Therapeutics, Inc., a Delaware corporation (the “Company”), and Yi Hua Chen (the “Holder”). WHEREAS, the Holder has acquired, from Alpha Capital Anstalt (“Alpha”), Alpha’s rights under Section 2.4 of the Securities Purchase Agreement dated February 26, 2024 betwe

Certificate of Designation of Series A2 Prefered Stock filed with the Secretary of State of Delaware on November 18, 2024.

Exhibit 3.2 QUALIGEN THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A-2 PREFERRED STOCK PURSUANT TO SECTION 151 OF THE Delaware GENERAL CORPORATION LAW The undersigned, Campbell Becher and Kevin Richardson II, do hereby certify that: 1. They are the President and Secretary, respectively, of Qualigen Therapeutics, Inc., a Delaware corporation (the “Co

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Qualigen Therapeutics, Inc. (Exact name of registr

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Comm

Director Agreement dated November 12, 2024 between the Company and Graydon Bensler

Exhibit 10.1 QUALIGEN THERAPEUTICS, INC. BOARD OF DIRECTORS AGREEMENT This BOARD OF DIRECTORS AGREEMENT (“Agreement”) by and between QUALIGEN THERAPEUTICS, INC., a Delaware corporation (the “Company”), and the undersigned signatory (the “Director”), provides for director services and shall become effective on November 7, 2024 (the “Effective Date”), according to the following terms and conditions:

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2024 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commi

Shares Expected to Begin Trading on Split-Adjusted Basis on November 5

Exhibit 99.1 Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024 CARLSBAD, Calif., November 1, 2024 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) announced today that it will implement a 1-for-50 reverse stock split of the issued shares of its common stock (the “Reverse Stock Split”), effective at 12:01 a.m. Eastern time on November 5, 2024.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2024 Qualigen Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2024 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commi

Certificate of Amendment of Amended and Restated Certificate of Incorporation filed on October 28, 2024.

Exhibit 3.1

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2024 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commi

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table FORM S-1 (Form Type) Qualigen Therapeutics, Inc.

Form of Lock-Up Agreement

Exhibit 10.31 Form of Lock-Up Agreement October [], 2024 Univest Securities, LLC 75 Rockefeller Plaza, Suite 1838 New York, New York 10019 Re: Qualigen Therapeutics, Inc.—Public Offering Ladies and Gentlemen: The undersigned, an officer, director and/or a holder of shares of common stock, $0.001 par value per share (the “Common Stock”), or rights to acquire Common Stock, of Qualigen Therapeutics,

Form of Pre-Funded Warrant

Exhibit 4.15 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK QUALIGEN THERAPEUTICS, INC. Warrant Shares: [] Initial Exercise Date: [] THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on

Consulting Agreement, between the Company and IR Agency, LLC

Exhibit 10.32 CONSULTING AGREEMENT IR Agency LLC (the “Consultant” or “IR Agency”) is pleased to provide certain consulting services to Qualigen Therapeutics Inc (“you,” the “Client” or the “Company”) as more fully described in this agreement (the “Agreement”). This Agreement sets forth the terms and conditions pursuant to which the Company engages the Consultant to provide such services. 1. Consu

Form of Securities Purchase Agreement

Exhibit 4.16 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of October [ ], 2024, between Qualigen Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and con

Form of Placement Agency Agreement

Exhibit 1.1 Placement Agency Agreement October [●], 2024 Qualigen Therapeutics, Inc. 5857 Owens Avenue, Suite 300 Carlsbad, California 92008 Attn: Kevin Richardson II, Interim Chief Executive Officer Dear Mr. Richardson: This letter (the “Agreement”) constitutes the agreement between Univest Securities, LLC, as placement agent (the “Placement Agent”), and Qualigen Therapeutics, Inc., a Delaware co

As filed with the Securities and Exchange Commission on October 24, 2024.

As filed with the Securities and Exchange Commission on October 24, 2024. Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Qualigen Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 26-3474527 (State or Other Jurisdiction of Incorporation or Organization) (

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 18, 2024 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commi

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 3, 2024 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commis

Director Agreement dated October 8, 2024 between the Company and Braeden Lichti

Exhibit 10.1 QUALIGEN THERAPEUTICS, INC. BOARD OF DIRECTORS AGREEMENT This BOARD OF DIRECTORS AGREEMENT (“Agreement”) by and between QUALIGEN THERAPEUTICS, INC., a Delaware corporation (the “Company”), and the undersigned signatory (the “Director”), provides for director services and shall become effective on October 8, 2024 (the “Effective Date”), according to the following terms and conditions:

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2024 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Com

Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel

Exhibit 99.1 Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel CARLSBAD, Calif., September 20, 2024 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced that on September 11, 2024, the Company received a notice from Nasdaq indicating that the Nasdaq Hearings Panel (“Panel”) has granted an extension for the continued listing of the Co

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2024 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

Form of Pre-Funded Warrant

Exhibit 4.1 PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK QUALIGEN THERAPEUTICS, INC. Warrant Shares: [] Initial Exercise Date: [], 2024 THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or

Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 6, 2024 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Comm

Placement Agent Agreement

Exhibit 10.1 Placement Agency Agreement [●], 2024 Qualigen Therapeutics, Inc. 5857 Owens Avenue, Suite 300 Carlsbad, California 92008 Attn: Michael S. Poirier, Chief Executive Officer Dear Mr. Poirier: This letter (the “Agreement”) constitutes the agreement between Univest Securities, LLC, as placement agent (the “Placement Agent”), and Qualigen Therapeutics, Inc., a Delaware corporation (the “Com

Form of Placement Agent Warrant

Exhibit 4.2 The number of shares of common stock issuable upon exercise of this Placement Agent Warrant may be less than the amounts set forth on the face hereof. This Placement Agent Warrant is issued pursuant to that certain Placement Agency Agreement, dated September 5, 2024, by and between the Company (as defined herein) and the Holder (as defined herein) (the “Placement Agency Agreement”). Ca

Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering

Exhibit 99.1 Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering CARLSBAD, Calif., September 6, 2024 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced the closing of its previously announced public offering of 14,724,058 shares of common stock, par value $0.001 per share (each a “Share,” and collectively, the “Shares”) at publi

Qualigen Therapeutics, Inc. 14,724,058 Shares of Common Stock 11,972,754 Pre-Funded Warrants to Purchase up to 11,972,754 Shares of Common Stock 11,972,754 Shares of Common Stock Underlying the Pre-Funded Warrants

PROSPECTUS Filed pursuant to Rule 424(b)(4) Registration No. 333-272623 Qualigen Therapeutics, Inc. 14,724,058 Shares of Common Stock 11,972,754 Pre-Funded Warrants to Purchase up to 11,972,754 Shares of Common Stock 11,972,754 Shares of Common Stock Underlying the Pre-Funded Warrants We are offering on a “reasonable best efforts” basis 14,724,058 million shares of common stock, par value $0.001 p

Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2024 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Comm

Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering

Exhibit 99.1 Qualigen Therapeutics, Inc. Announces Pricing of $3.46 Million Public Offering CARLSBAD, Calif., September 5, 2024 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (the “Company”) today announced the pricing of a public offering of 14,724,058 shares of common stock, par value $0.001 per share (each a “Share,” and collectively, the “Shares”) at a public offering price of $

Qualigen Therapeutics, Inc. 5857 Owens Avenue, Suite 300 Carlsbad, California 92008 August 29, 2024

Qualigen Therapeutics, Inc. 5857 Owens Avenue, Suite 300 Carlsbad, California 92008 August 29, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Doris Stacey Gama, Jason Drory Re: Qualigen Therapeutics, Inc. Registration Statement on Form S-1 File 333-272623 Ladies and Gentlemen: Pursuant to Rule 461 under the Sec

Univest Securities, LLC 75 Rockefeller Plaza 18C New York, NY 10019

Univest Securities, LLC 75 Rockefeller Plaza 18C New York, NY 10019 August 29, 2024 VIA EDGAR CORRESPONDENCE U.

As filed with the Securities and Exchange Commission on August 22, 2024.

As filed with the Securities and Exchange Commission on August 22, 2024. Registration No. 333-272623 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 5 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Qualigen Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 26-3474527 (State or Other Jurisdiction of Inc

Form of Placement Agency Agreement

Exhibit 1.1 Placement Agency Agreement [●], 2024 Qualigen Therapeutics, Inc. 5857 Owens Avenue, Suite 300 Carlsbad, California 92008 Attn: Michael S. Poirier, Chief Executive Officer Dear Mr. Poirier: This letter (the “Agreement”) constitutes the agreement between Univest Securities, LLC, as placement agent (the “Placement Agent”), and Qualigen Therapeutics, Inc., a Delaware corporation (the “Comp

Form of Securities Purchase Agreement

Exhibit 4.16 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of [●], 2024, between Qualigen Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table FORM S-1 (Form Type) Qualigen Therapeutics, Inc.

Form of Pre-Funded Warrant

Exhibit 4.15 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK QUALIGEN THERAPEUTICS, INC. Warrant Shares: [] Initial Exercise Date: [] THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on

Form of Placement Agency Warrant

Exhibit 4.17 The number of shares of common stock issuable upon exercise of this Placement Agent Warrant may be less than the amounts set forth on the face hereof. This Placement Agent Warrant is issued pursuant to that certain Placement Agency Agreement, dated August [], 2024, by and between the Company (as defined herein) and the Holder (as defined herein) (the “Placement Agency Agreement”). Cap

Form of Lock-Up Agreement

Exhibit 10.31 Form of Lock-Up Agreement August [], 2024 Univest Securities, LLC 75 Rockefeller Plaza, Suite 1838 New York, New York 10019 Re: Qualigen Therapeutics, Inc.—Public Offering Ladies and Gentlemen: The undersigned, an officer, director and/or a holder of shares of common stock, $0.001 par value per share (the “Common Stock”), or rights to acquire Common Stock, of Qualigen Therapeutics, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Qualigen Therapeutics, Inc. (Exact name of registrant a

Qualigen Therapeutics, Inc. 5857 Owens Avenue, Suite 300 Carlsbad, California 92008 August 12, 2024

Qualigen Therapeutics, Inc. 5857 Owens Avenue, Suite 300 Carlsbad, California 92008 August 12, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Doris Stacey Gama, Jason Drory Re: Qualigen Therapeutics, Inc. Registration Statement on Form S-1 File 333-272623 Ladies and Gentlemen: Pursuant to Rule 461 under the Sec

Qualigen Therapeutics, Inc. 5857 Owens Avenue, Suite 300 Carlsbad, California 92008 August 12, 2024

Qualigen Therapeutics, Inc. 5857 Owens Avenue, Suite 300 Carlsbad, California 92008 August 12, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Doris Stacey Gama, Jason Drory Re: Withdrawal of Acceleration Request on the Registration Statement on Form S-1 (File No. 333-272623) Ladies and Gentlemen: Reference is m

UNIVEST SECURITIES, LLC 75 ROCKEFELLER PLAZA 18C NEW YORK, NY 10019

UNIVEST SECURITIES, LLC 75 ROCKEFELLER PLAZA 18C NEW YORK, NY 10019 August 12, 2024 VIA EDGAR CORRESPONDENCE U.

Univest Securities, LLC 75 Rockefeller Plaza 18C New York, NY 10019

Univest Securities, LLC 75 Rockefeller Plaza 18C New York, NY 10019 August 12, 2024 VIA EDGAR CORRESPONDENCE U.

Form of Pre-Funded Warrant

Exhibit 4.15 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK QUALIGEN THERAPEUTICS, INC. Warrant Shares: [] Initial Exercise Date: [] THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on

Form of Lock-Up Agreement

Exhibit 10.31 Form of Lock-Up Agreement August [], 2024 Univest Securities, LLC 75 Rockefeller Plaza, Suite 1838 New York, New York 10019 Re: Qualigen Therapeutics, Inc.—Public Offering Ladies and Gentlemen: The undersigned, an officer, director and/or a holder of shares of common stock, $0.001 par value per share (the “Common Stock”), or rights to acquire Common Stock, of Qualigen Therapeutics, I

Form of Placement Agency Agreement

Exhibit 1.1 Placement Agency Agreement [●], 2024 Qualigen Therapeutics, Inc. 5857 Owens Avenue, Suite 300 Carlsbad, California 92008 Attn: Michael S. Poirier, Chief Executive Officer Dear Mr. Poirier: This letter (the “Agreement”) constitutes the agreement between Univest Securities, LLC, as placement agent (the “Placement Agent”), and Qualigen Therapeutics, Inc., a Delaware corporation (the “Comp

Form of Placement Agency Warrant

Exhibit 4.17 The number of shares of common stock issuable upon exercise of this Placement Agent Warrant may be less than the amounts set forth on the face hereof. This Placement Agent Warrant is issued pursuant to that certain Placement Agency Agreement, dated August [], 2024, by and between the Company (as defined herein) and the Holder (as defined herein) (the “Placement Agency Agreement”). Cap

As filed with the Securities and Exchange Commission on August 9, 2024.

As filed with the Securities and Exchange Commission on August 9, 2024. Registration No. 333-272623 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 4 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Qualigen Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 26-3474527 (State or Other Jurisdiction of Inco

1185 AVENUE OF THE AMERICAS | 31ST FLOOR | NEW YORK, NY | 10036 T (212) 930-9700 | F (212) 930-9725 | WWW.SRFC.LAW

August 9, 2024 Via EDGAR Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission Washington, D.

Form of Securities Purchase Agreement

Exhibit 4.16 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of [●], 2024, between Qualigen Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions

As filed with the Securities and Exchange Commission on August 7, 2024.

As filed with the Securities and Exchange Commission on August 7, 2024. Registration No. 333-272623 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Qualigen Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 26-3474527 (State or Other Jurisdiction of Inco

Form of Securities Purchase Agreement

Exhibit 4.16 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of [●], 2024, between Qualigen Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions

Form of Lock-Up Agreement

Exhibit 10.31 Form of Lock-Up Agreement August [], 2024 Univest Securities, LLC 75 Rockefeller Plaza, Suite 1838 New York, New York 10019 Re: Qualigen Therapeutics, Inc.—Public Offering Ladies and Gentlemen: The undersigned, an officer, director and/or a holder of shares of common stock, $0.001 par value per share (the “Common Stock”), or rights to acquire Common Stock, of Qualigen Therapeutics, I

Form of Placement Agency Warrant

Exhibit 4.17 The number of shares of common stock issuable upon exercise of this Placement Agent Warrant may be less than the amounts set forth on the face hereof. This Placement Agent Warrant is issued pursuant to that certain Placement Agency Agreement, dated August [], 2024, by and between the Company (as defined herein) and the Holder (as defined herein) (the “Placement Agency Agreement”). Cap

Form of Pre-Funded Warrant

Exhibit 4.15 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK QUALIGEN THERAPEUTICS, INC. Warrant Shares: [] Initial Exercise Date: [] THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on

Form of Placement Agency Agreement

Exhibit 1.1 Placement Agency Agreement [●], 2024 Qualigen Therapeutics, Inc. 5857 Owens Avenue, Suite 300 Carlsbad, California 92008 Attn: Michael S. Poirier, Chief Executive Officer Dear Mr. Poirier: This letter (the “Agreement”) constitutes the agreement between Univest Securities, LLC, as placement agent (the “Placement Agent”), and Qualigen Therapeutics, Inc., a Delaware corporation (the “Comp

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2024 Qualigen Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 2, 2024 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2024 Qualigen Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2024 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commissi

Promissory Note, dated July 12, 2024, issued by Qualigen Therapeutics, Inc. to Marizyme, Inc. (Incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed July 18, 2024.)

Exhibit 10.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2024 Qualigen Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2024 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commissi

Senior Note dated July 8, 2024 (Incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K filed July 15, 2024.)

Exhibit 10.2 THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVA

Letter from Baker Tilly US, LLP, addressed to the Securities and Exchange Commission, dated July 15, 2024.

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2024 Qualigen Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2024 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2024 Qualigen Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2024 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commissio

Securities Purchase Agreement dated July 5, 2024. (Incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed July 11, 2024.)

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 5, 2024 between Qualigen Therapeutics, Inc., a Delaware corporation (the “Company”), and the purchaser identified on the Annex A hereto (including its successors and assigns, the “Investor”. WHEREAS, the Investor wishes to purchase from the Company, and the Company wishes to issue a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Qualigen Therapeutics, Inc. (Exact name of registrant

Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination

Exhibit 99.1 Qualigen Therapeutics, Inc. Received Nasdaq Notice of a Delisting Determination CARLSBAD, Calif., May 30, 2024 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), announced today that on May 23, 2024, it received written notice (the “Delist Notice”) from The Nasdaq Stock Market (“Nasdaq”) indicating the Company’s continued non-compliance with th

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2024 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commissio

Read Instruction (on back page) Before Preparing Form. Please Print or Type. Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 001-37428 NOTIFICATION OF LATE FILING CUSIP NUMBER 74754R202 (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2024

As filed with the Securities and Exchange Commission on May 3, 2024.

As filed with the Securities and Exchange Commission on May 3, 2024. Registration No. 333-272623 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Qualigen Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 26-3474527 (State or Other Jurisdiction of Incorpo

5,157,087 Shares Common Stock

Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-269088 PROSPECTUS 5,157,087 Shares Common Stock This prospectus relates to the resale or other disposition from time to time by the selling stockholder named herein of up to an aggregate of 5,157,087 shares of our common stock, par value $0.001 per share (the “Resale Shares”), which may be issuable to the selling stockholder pursuant

As filed with the Securities and Exchange Commission on April 30, 2024

As filed with the Securities and Exchange Commission on April 30, 2024 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Qualigen Therapeutics, Inc.

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2024 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commiss

Marizyme Enters into Co-Development Agreement with Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™

Exhibit 99.1 Marizyme Enters into Co-Development Agreement with Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft™ JUPITER, FL, April 16, 2024 (GLOBE NEWSWIRE) — via NewMediaWire — Marizyme, Inc. (“Marizyme”, OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics, Inc. (“Qualigen”) (NASDAQ: QLGN) to advance the commercialization

Common Stock Purchase Warrant for 1,800,032 shares in favor of Yi Hua Chen, dated April 12, 2024

Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

8% Convertible Debenture due December 31, 2024 in favor of Yi Hua Chen

Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS

Co-Development Agreement, dated April 11, 2024, between Qualigen Therapeutics, Inc. and Marizyme, Inc.

Exhibit 10.4 CO-DEVELOPMENT AGREEMENT THIS CO-DEVELOPMENT AGREEMENT (this “Agreement”) is entered into as of April 11, 2024, and effective as of the date the Initial Payment (defined below) is made (the “Effective Date”), by and between Marizyme, Inc., a Nevada corporation (the “Company”) and Qualigen Therapeutics, Inc., a Delaware corporation (“Qualigen”). The Company and Qualigen are sometimes r

Option Exercise, dated April 11, 2024, by Yi Hua Chen, agreed to by Alpha Capital Anstalt and by Qualigen Therapeutics, Inc.

Exhibit 10.1 OPTION EXERCISE Yi Hua Chen (“Chen”) hereby represents to Qualigen Therapeutics, Inc. (“Qualigen”) that Chen has acquired, from Alpha Capital Anstalt (“Alpha”), Alpha’s rights under Section 2.4 of the Securities Purchase Agreement dated February 26, 2024 between Qualigen and Alpha (the “Alpha SPA”). Section 2.4 of the Alpha SPA provides that “Each Purchaser shall have the right to pur

Clawback Policy

Exhibit 97.1 CLAWBACK POLICY QUALIGEN THERAPEUTICS, INC. Purpose Qualigen Therapeutics, Inc. (the “Company”) is establishing this policy to align the interests of executive officers of the Company with those of shareholders, to create and maintain a culture that emphasizes integrity and accountability and to enforce the Company’s pay-for-performance compensation philosophy. This policy provides fo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37428 Qualigen Therapeutics, Inc. (Exact name of registrant as spe

Subsidiaries of the Registrant

Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT None.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response 2.50 FORM 12b-25 SEC FILE NUMBER 001-37428 NOTIFICATION OF LATE FILING CUSIP NUMBER 74754R202 (Check one): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2

Termination Agreement dated as of March 16, 2024 between the Company and Pan-RAS Holdings, Inc.

Exhibit 10.1 TERMINATION AGREEMENT - LICENSE AND SUBLICENSE AGREEMENT Reference is made to that certain License and Sublicense Agreement (“Agreement”) entered into as of February 15, 2024 by Qualigen Therapeutics, Inc., a Delaware corporation (“QLGN”), on the one hand, and Pan-RAS Holdings, Inc., a New York corporation (“Pan-RAS”), on the other hand. QLGN and Pan-RAS are collectively referred to a

Termination of a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2024 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commiss

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 25, 2024 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Comm

Common Stock Purchase Warrant for 900,016 shares in favor of Alpha Capital Anstalt, dated February 27, 2024

Exhibit 10.3 EXHIBIT C NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECT

Securities Purchase Agreement, dated February 26, 2024, by and between Qualigen Therapeutics, Inc. and Alpha Capital Anstalt

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 27, 2024, between Qualigen Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and co

8% Convertible Debenture Due December 31, 2024 in favor of Alpha Capital Anstalt

Exhibit 10.2 EXHIBIT A NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFEC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2024 Qualigen Therap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2024 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Comm

License and Sublicense Agreement dated February 15, 2024 between the Company and Pan-RAS Holdings, Inc.

Exhibit 10.1 LICENSE AND SUBLICENSE AGREEMENT This License and Sublicense Agreement (this “Agreement”) is entered into as of February 15, 2024 (the “Effective Date”) by Qualigen Therapeutics, Inc., a Delaware corporation (“QLGN”), on the one hand, and Pan-RAS Holdings, Inc., a New York corporation (“Pan-RAS”), on the other hand. Reference is made to the Exclusive License Agreement dated July 17, 2

Amendment No. 1 with regard to Securities Purchase Agreement dated December 5, 2023 with Alpha Capital Anstalt

Exhibit 10.1 Amendment No. 1 with regard to Securities Purchase Agreement This Amendment No. 1 (“Amendment”) is made between the undersigned parties to that certain Securities Purchase Agreement between them dated December 21, 2022 (the “SPA”). All capitalized terms used but not defined herein shall have the meanings ascribed to them in the SPA or in the outstanding Debenture or the outstanding Wa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2023 Qualigen Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2023 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commi

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2023 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Qualigen Therapeutics, Inc. (Exact name of registr

Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023

Exhibit 99.1 Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023 ● Initiated dosing of three patients in first cohort of Phase 1 clinical trial of QN-302 for treatment of advanced or metastatic solid tumors ● Phase 1a patient recruitment ongoing; company anticipates sharing update on safety and preliminary efficacy in second quarter of 2024 ● Expect to select lead Pa

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Comm

Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors

Exhibit 99.1 Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors CARLSBAD, Calif., Nov. 7th, 2023 (GLOBE NEWSWIRE) – Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation

Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commi

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2023 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commi

Corporate Presentation of Qualigen Therapeutics, Inc. dated October 2023

Exhibit 99.1

As filed with the Securities and Exchange Commission on October 2, 2023.

As filed with the Securities and Exchange Commission on October 2, 2023. Registration No. 333-272623 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Qualigen Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 26-3474527 (State or Other Jurisdiction of Inc

1221 McKinney Street

1221 McKinney Street Suite 2100 Houston, TX 77010 +1 713 469 3800 Fax +1 713 469 3899 reedsmith.

3,958,537 Shares Common Stock

Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-269088 PROSPECTUS 3,958,537 Shares Common Stock This prospectus relates to the resale or other disposition from time to time by the selling stockholder named herein of up to an aggregate of 3,958,537 shares of our common stock, par value $0.001 per share (the “Resale Shares”), which may be issued to the selling stockholder pursuant to

Consent and Waiver dated September 22, 2023, between Qualigen Therapeutics, Inc. and Alpha Capital Anstalt.

Exhibit 10.1 Qualigen Therapeutics, Inc. 5857 Owens Avenue, Suite 300 Carlsbad, CA 92008 USA September 22, 2023 Alpha Capital Anstalt Altenbach 8 9490 Vaduz, Liechtenstein Copy to: LH Financial Services Corp. 510 Madison Avenue, 14th Floor New York, NY 10022 Re: Consent and Waiver Regarding the Monthly Redemption Amount under the Debenture for October 2023 Dear Sirs: Reference is hereby made to th

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2023 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction (Commission (I.R.S. Em

As filed with the Securities and Exchange Commission on September 1, 2023

As filed with the Securities and Exchange Commission on September 1, 2023 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Qualigen Therapeutics, Inc.

QUALIGEN THERAPEUTICS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE LOSS

Exhibit 99.1 Qualigen Therapeutics, Inc. Reports Financial Results and Corporate Update for Quarter Ending June 30, 2023 Investigational New Drug (IND) clearance transitions Qualigen from preclinical to clinical-stage company Company divests FastPack® diagnostics business for approximately $5 million in all cash transaction to support advancement of therapeutics pipeline CARLSBAD, Calif., Aug. 15t

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2023 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction (Commission (I.R.S. Emplo

Separation Agreement and General Release dated June 20, 2023 with Amy Broidrick

Exhibit 10.1 SEPARATION AGREEMENT AND GENERAL RELEASE 1. Purpose of Agreement: The intent of this Separation Agreement and General Release (“Agreement”) is to amicably and finally resolve and compromise all issues and claims surrounding the employment of Amy Broidrick (“Employee”) with Qualigen, Inc. (“Employer”) and the termination thereof. This Agreement becomes effective on the eighth day after

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Qualigen Therapeutics, Inc. (Exact name of registrant a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2023 Qualigen Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2023 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commiss

Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors Investigational New Drug (IND) clearance transitions Qualigen Therapeutics from preclinical to clin

Exhibit 99.1 Qualigen Therapeutics Announces US FDA IND Clearance to Initiate Phase 1 Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors Investigational New Drug (IND) clearance transitions Qualigen Therapeutics from preclinical to clinical-stage company and demonstrates leadership in G4-targeting therapies for areas of high unmet need in oncology CARLSBAD, Calif., Augus

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2023 Qualigen Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2023 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commiss

Amendment and Settlement Agreement dated July 19, 2023 with NanoSynex, Ltd

Exhibit 10.1 AMENDMENT AND SETTLEMENT AGREEMENT This Amendment and Settlement Agreement (this “Agreement”) is made with effect as of this 19th day of July 2023, by and between Qualigen Therapeutics, Inc., a Delaware corporation based in California, U.S., (“Qualigen”) and NanoSynex Ltd., a private Israeli company (“Nano”). Each of Qualigen and Nano may be referred to hereinafter as a “Party” and co

Stock Purchase Agreement dated July 20, 2023 with Chembio Diagnostics, Inc., Biosynex, S.A. and Qualigen, Inc.

Exhibit 2.1 Execution Version STOCK PURCHASE AGREEMENT by and among Qualigen Therapeutics, Inc., Chembio Diagnostics, Inc., Biosynex, S.A., and Qualigen, Inc., dated as of July 20, 2023 TABLE OF CONTENTS ARTICLE I DEFINITIONS 4 ARTICLE II PURCHASE AND SALE 16 Section 2.01 Purchase and Sale. 16 Section 2.02 Purchase Price. 16 Section 2.03 Closing Estimates; Closing Payments. 16 Section 2.04 Post-Cl

All cash deal with Chembio Diagnostics, a US Subsidiary of the French Diagnostics Company BIOSYNEX, SA, solidifies Qualigen’s strategic priority on therapeutics

Exhibit 99.1 Qualigen Therapeutics Divests FastPack® Diagnostics Business All cash deal with Chembio Diagnostics, a US Subsidiary of the French Diagnostics Company BIOSYNEX, SA, solidifies Qualigen’s strategic priority on therapeutics CARLSBAD, Calif., July 24, 2023 (GLOBE NEWSWIRE) – Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a therapeutics company focused on developing treatments for adult and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2023 Qualigen Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2023 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commissi

Unaudited Pro Forma Condensed Consolidated Financial Information

Exhibit 99.2 Unaudited Pro Forma Condensed Consolidated Financial Information Stock Purchase Agreement with Chembio Diagnostics, Inc. and Biosynex, S.A. On July 20, 2023 (the “Closing Date”), Qualigen Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a stock purchase agreement (the “Purchase Agreement”) with Chembio Diagnostics, Inc. (the “Buyer”), Biosynex, S.A. (“Biosynex”

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2023 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commissi

Description of Common Stock

Exhibit 4.9 QUALIGEN THERAPEUTICS, INC. DESCRIPTION OF COMMON STOCK Qualigen Therapeutics, Inc. (the “Company”) has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) – common stock, par value $0.001 per share (the “Common Stock”). The Common Stock trades on The Nasdaq Capital Market under the trading symbol “QLGN.” The follo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37428 Qualigen Therapeutics, Inc. (Exact name

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2023 Qualigen Therapeuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2023 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commissi

As filed with the Securities and Exchange Commission on June 13, 2023.

As filed with the Securities and Exchange Commission on June 13, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Qualigen Therapeutics, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 2834 26-3474527 (State or Other Jurisdiction of Incorporation or Organization)

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table FORM S-1 (Form Type) Qualigen Therapeutics, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 Qualigen Therapeutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Qualigen Therapeutics, Inc. (Exact name of registrant

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commission

Letter to Tariq Arshad, dated January 13, 2023, regarding compensatory changes

Exhibit 10.33 Amendment to Executive Employment Agreement with Tariq Arshad, dated January 13, 2023 January 13, 2023 Dear Dr. Arshad: As you may know, on January 13, 2023, the board of directors of Qualigen Therapeutics, Inc. (the “Company”), as part of certain cost-cutting measures across the Company, approved a temporary 20% reduction to the base salaries of all executive officers of the Company

Letter to Amy Broidrick, dated January 13, 2023, regarding compensatory changes

Exhibit 10.32 Amendment to Executive Employment Agreement with Amy Broidrick, dated January 13, 2023 January 13, 2023 Dear Ms. Broidrick: As you know, on January 13, 2023, the board of directors of Qualigen Therapeutics, Inc. (the “Company”), as part of certain cost-cutting measures across the Company, approved a temporary 20% reduction to the base salaries of all executive officers of the Company

Amendment 2 to the Exclusive License Agreement (QN-247), by and between Qualigen, Inc. and University of Louisville Research Foundation, Inc., dated January 17, 2023

Exhibit 10.9

First Deed of Variation to License Agreement with UCL Business Limited dated March 30, 2022

Exhibit 10.21 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. First Deed of Variation THIS DEED OF VARIATION is made as of the 30th day of March 2022 BETWEEN (1) UCL

Amendment 1 to the Exclusive License Agreement (RAS), by and between Qualigen, Inc. and University of Louisville Research Foundation, Inc., dated March 16, 2021

Exhibit 10.11

Power of Attorney (included on signature page)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37428 Qualigen Therapeutics, Inc. (Exact name of registrant as spe

Letter to Michael Poirier, dated January 13, 2023, regarding compensatory changes

Exhibit 10.31 Amendment to Executive Employment Agreement with Michael P. Poirier, dated January 13, 2023 January 13, 2023 Dear Mr. Poirier: As you know, on January 13, 2023, the board of directors of Qualigen Therapeutics, Inc. (the “Company”), as part of certain cost-cutting measures across the Company, approved a temporary 20% reduction to the base salaries of all executive officers of the Comp

Exclusive License Agreement between the Company and University of Louisville Research Foundation (RAS), Inc., dated as of July 17, 2020

Exhibit 10.10

Amendment 1 to the Exclusive License Agreement (QN-247), by and between Qualigen, Inc. and University of Louisville Research Foundation, Inc., dated March 16, 2021

Exhibit 10.8

Subsidiaries of the Registrant

Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Qualigen, Inc. – a Delaware corporation. NanoSynex Ltd. – a company incorporated under the laws of the State of Israel

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2023 Qualigen Therapeut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2023 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commiss

Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing

Exhibit 99.1 Qualigen Therapeutics, Inc. Receives Nasdaq Notice Regarding Delayed Form 10-K Filing CARLSBAD, Calif., April 21, 2023 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diag

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC FILE NUMBER: 001-37428 CUSIP NUMBER: 74754R103 (Check One): ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2022 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on Form N-SAR For the Transition Period Ended: Read Instruction (on back page) Before Preparing Form.

Corporate Presentation of Qualigen Therapeutics, Inc. dated February 2023

Exhibit 99.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2023 Qualigen Therap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2023 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Comm

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2023 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commi

Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302

Exhibit 99.1 Qualigen Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for QN-302, a G-Quadruplex (G4) Transcription Inhibitor for the Intended Indication of Pancreatic Cancer CARLSBAD, Calif., January 10, 2023 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing

Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2023 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commi

January 3, 2023

CORRESP 1 filename1.htm January 3, 2023 VIA EDGAR United States Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Attention: Joshua Gorsky Re: Qualigen Therapeutics, Inc. – Request for Acceleration Registration Statement on Form S-3 File No. 333- 269088 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Qualigen Therapeutic

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Qualigen Therapeutics, Inc.

As filed with the Securities and Exchange Commission on December 30, 2022

As filed with the Securities and Exchange Commission on December 30, 2022 Registration No.

Registration Rights Agreement, dated December 22, 2022, by and between Qualigen Therapeutics, Inc. and Alpha Capital Anstalt

Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of December 22, 2022, between Qualigen Therapeutics, Inc., a Delaware corporation (the “Company”), and the purchaser signatory hereto (the “Purchaser”). This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and

8% Senior Convertible Debenture Due December 22, 2025 in favor of Alpha Capital Anstalt

Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS CONVERTIBLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIS

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 21, 2022 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Comm

Securities Purchase Agreement, dated December 21, 2022, by and between Qualigen Therapeutics, Inc. and Alpha Capital Anstalt

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of December 21, 2022, between Qualigen Therapeutics, Inc., a Delaware corporation (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively, the ?Purchasers?). WHEREAS, subject to the terms and co

Common Stock Purchase Warrant for 2,500,000 shares in favor of Alpha Capital Anstalt, dated December 22, 2022

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2022 Qualigen Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2022 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commi

Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Exhibit 99.1 Qualigen Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule CARLSBAD, Calif., December 12, 2022 (GLOBE NEWSWIRE) - Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics

Qualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock Split Action to comply with continued listing requirements for Nasdaq Capital Market

Exhibit 99.1 Qualigen Therapeutics, Inc. Announces 1-for-10 Reverse Stock Split Action to comply with continued listing requirements for Nasdaq Capital Market CARLSBAD, Calif., November 22, 2022 — Qualigen Therapeutics, Inc. (Nasdaq: QLGN Qualigen Therapeutics, Inc.), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2022 Qualigen Therap

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2022 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Comm

Amendment No. 1 to the 2022 Employee Stock Purchase Plan of Qualigen Therapeutics, Inc.

Exhibit 10.2 AMENDMENT NO. 1 to the 2022 EMPLOYEE STOCK PURCHASE PLAN of QUALIGEN THERAPEUTICS, INC. (Effective November 23, 2022) This Amendment No. 1 (this “Amendment”) to the 2022 Employee Stock Purchase Plan of Qualigen Therapeutics, Inc. (the “Company”) is hereby adopted by the Board of Directors of the Company (the “Board”), effective as of the date first referenced above. WHEREAS, the 2022

Certificate of Amendment to the Amended and Restated Certificate of Incorporation, filed with the Delaware Secretary of State on November 21, 2022

Exhibit 3.1 QUALIGEN THERAPEUTICS, INC. CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION Qualigen Therapeutics, Inc. (the “Corporation”), a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that: 1. The name of the corporation is Qualigen Therapeutics, Inc. 2. This Certificate of Ame

Amendment No. 2 to the 2020 Stock Incentive Plan of Qualigen Therapeutics, Inc.

Exhibit 10.1 AMENDMENT NO. 2 to the 2020 STOCK INCENTIVE PLAN of QUALIGEN THERAPEUTICS, INC. (Effective November 23, 2022) This Amendment No. 2 (this “Amendment”) to the 2020 Stock Incentive Plan of Qualigen Therapeutics, Inc. (the “Company”) is hereby adopted by the Board of Directors of the Company (the “Board”), effective as of the date first referenced above. WHEREAS, the 2020 Stock Incentive

Qualigen Therapeutics, Inc. 2022 Employee Stock Purchase Plan

Exhibit 10.1 QUALIGEN THERAPEUTICS, INC. 2022 EMPLOYEE STOCK PURCHASE PLAN As adopted by the Board of Directors on July 8, 2022 As approved by the Stockholders on August 25, 2022 ARTICLE 1 PURPOSE; TERM 1.1 Purpose. The purposes of the Plan are to (a) enhance the Company?s ability to attract and retain the services of Eligible Employees upon whose judgment, initiative and efforts the successful co

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Qualigen Therapeutics, Inc. (Exact name of registr

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2022 Qualigen Therape

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2022 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commi

Corporate Slide Presentation of Qualigen Therapeutics, Inc. dated October 2022

Exhibit 99.1

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2022 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934

DEFA14A 1 form-defa14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2022 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Comm

Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 25, 2022 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commis

Qualigen Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update Q2 2022 FastPack ® Sales increased approximately 28%, and gross profit on product sales was up 64% year-over-year from Q2 2021 Milestone achieveme

Exhibit 99.1 Qualigen Therapeutics, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update Q2 2022 FastPack ? Sales increased approximately 28%, and gross profit on product sales was up 64% year-over-year from Q2 2021 Milestone achievements in QN-302 and QN-247 oncology therapeutic programs and acquisition of majority stake in NanoSynex strengthen Company?s diversified pr

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2022 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Qualigen Therapeutics, Inc. (Exact name of registrant a

2042 Corte del Nogal, Carlsbad, CA 92011 Tel 877.709.2169 Fax 760.918.9165 www.qualigeninc.com

CORRESP 1 filename1.htm August 3, 2022 VIA EDGAR United States Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Attention: Doris Stacey Gama Re: Qualigen Therapeutics, Inc. – Request for Acceleration Registration Statement on Form S-3 File No. 333- 266430 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Qualigen Therapeu

August 1, 2022

DEL AM 1 formdelam.htm August 1, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Re: Qualigen Therapeutics, Inc. Registration Statement on Form S-3 (File No. 333-266430) Ladies and Gentlemen: Reference is made to the Registration Statement on Form S-3 (File No. 333-266430) filed with the Securities and Exchange

Form of Subordinated Indenture

Exhibit 4.29 QUALIGEN THERAPEUTICS, INC. INDENTURE Dated as of , 20 [ ] Trustee Subordinated Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 4 Section 1.4 Rules of Construction 4 ARTICLE 2 THE SECURITIES 5 Section 2.1 Issuable in Series 5

As filed with the Securities and Exchange Commission on July 29, 2022

As filed with the Securities and Exchange Commission on July 29, 2022 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Qualigen Therapeutics, Inc.

Form of Senior Indenture

Exhibit 4.28 QUALIGEN THERAPEUTICS, INC. INDENTURE Dated as of , 20 [ ] Trustee Senior Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 4 Section 1.4 Rules of Construction 4 ARTICLE 2 THE SECURITIES 5 Section 2.1 Issuable in Series 5 S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934

PRE 14A 1 formpre14a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant To Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

2042 Corte del Nogal, Carlsbad, CA 92011 Tel 877.709.2169 Fax 760.918.9165 www.qualigeninc.com

CORRESP 1 filename1.htm June 27, 2022 VIA EDGAR United States Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Attention: Doris Stacey Gama Re: Qualigen Therapeutics, Inc. – Request for Acceleration Registration Statement on Form S-3 File No. 333- 265691 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Qualigen Therapeut

As filed with the Securities and Exchange Commission on June 17, 2022

As filed with the Securities and Exchange Commission on June 17, 2022 Registration No.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Qualigen Therapeutics, Inc.

Pre-Funded Common Stock Purchase Warrant issued by the Company in favor of Alpha Capital Anstalt, dated May 26, 2022

Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2022 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commissio

Qualigen Therapeutics Acquires Majority Stake in Infectious Disease Diagnostics Technology Company NanoSynex Transaction expected to significantly advance commercial readiness of NanoSynex’s innovative diagnostics technology platform focused on the $

Exhibit 99.1 Qualigen Therapeutics Acquires Majority Stake in Infectious Disease Diagnostics Technology Company NanoSynex Transaction expected to significantly advance commercial readiness of NanoSynex?s innovative diagnostics technology platform focused on the $30+ Billion global infectious disease testing market Company to hold conference call today, June 2, 2022 at 1:00PM ET to discuss latest c

Master Agreement for the Operational and Technological Funding of NanoSynex between Qualigen Therapeutics, Inc. and NanoSynex Ltd., dated May 26, 2022

Exhibit 10.1 MASTER AGREEMENT FOR THE OPERATIONAL AND TECHNOLOGY FUNDING OF NANOSYNEX LTD. THIS MASTER AGREEMENT FOR THE OPERATIONAL AND TECHNOLOGY FUNDING OF NANOSYNEX LTD. (this ?Agreement?), dated as of May 26, 2022, is entered into by and among NanoSynex Ltd., a company incorporated under the laws of the State of Israel (the ?Company?) and Qualigen Therapeutics Inc. a Delaware corporation base

QLGN / Qualigen Therapeutics, Inc. / ALPHA CAPITAL ANSTALT - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1) QUALIGEN THERAPEUTICS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 (Title of Class of Securities) 74754R103 (CUSIP Number) May 26, 2022 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) Check the appropriate box to designate the rule purs

Results of Operations and Financial Condition, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2022 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Qualigen Therapeutics, Inc. (Exact name of registrant

Share Purchase Agreement between the Company and Alpha Capital Anstalt dated April 29, 2022

Exhibit 10.2 SHARE PURCHASE AGREEMENT THIS SHARE PURCHASE AGREEMENT (this ?Agreement?) is made and entered into as of April 29, 2022 (the ?Effective Date?), by and between Qualigen Therapeutics Inc. (the ?Purchaser?) and Alpha Capital Anstalt (the ?Seller?). W I T N E S S E T H: WHEREAS, the Seller owns and desires to sell 2,232,861 Preferred A-1 Shares, nominal value NIS 0.01 each (the ?Purchased

Qualigen Therapeutics, Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results

Exhibit 99.1 Qualigen Therapeutics, Inc. Provides Corporate Update and Reports First Quarter 2022 Financial Results CARLSBAD, Calif., May 13, 2022 ? Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces its fi

Amended and Restated Common Stock Purchase Warrant to GreenBlock Capital LLC, dated April 25, 2022

Exhibit 4.15 AMENDED AND RESTATED COMMON STOCK PURCHASE WARRANT QUALIGEN THERAPEUTICS, INC. Warrant Shares: 300,000 Initial Exercisability Date: January 26, 2022 (from December 3, 2021) THIS AMENDED AND RESTATED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, GreenBlock Capital LLC or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limita

Series B Preferred Share Purchase Agreement between the Company and NanoSynex Ltd. dated April 29, 2022

Exhibit 10.1 SERIES B PREFERRED SHARE PURCHASE AGREEMENT THIS SERIES B PREFERRED SHARE PURCHASE AGREEMENT (this ?Agreement?) is made and entered into on April 29, 2022, by and among NanoSynex Ltd., a company established under the laws of the State of Israel (the ?Company?), and Qualigen Therapeutics Inc. (the ?Investor?). The Company and the Investor may also be referred to hereinafter as the ?Par

Amended and Restated Common Stock Purchase Warrant to Christopher Nelson, dated April 25, 2022

Exhibit 4.16 AMENDED AND RESTATED COMMON STOCK PURCHASE WARRANT QUALIGEN THERAPEUTICS, INC. Warrant Shares: 300,000 Initial Exercisability Date: January 26, 2022 (from December 3, 2021) THIS AMENDED AND RESTATED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, Christopher Nelson or his assigns (the ?Holder?) is entitled, upon the terms and subject to the limitation

Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2022 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commiss

Qualigen Therapeutics to Acquire Majority Stake in Diagnostics Technology Company NanoSynex Companies to Collaborate in the Development of Innovative Diagnostics Platform to Combat “Superbugs”, a Rising Global Health Crisis

Exhibit 99.1 Qualigen Therapeutics to Acquire Majority Stake in Diagnostics Technology Company NanoSynex Companies to Collaborate in the Development of Innovative Diagnostics Platform to Combat ?Superbugs?, a Rising Global Health Crisis CARLSBAD, Calif., May 3, 2022 (GLOBE NEWSWIRE) ? Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments f

Hire offer letter from the Company to Tariq Arshad, dated April 22, 2021

Exhibit 10.56 April 22, 2021 Full-Time Employment Offer Dear Dr. Arshad, We are pleased to offer you the position of Senior Vice President & Chief Medical Officer with Qualigen Therapeutics, Inc. (the ?Company?). This position and its responsibilities will utilize your talents, education and experience to meet the Company?s needs in this important area. (You would also serve in the same capacity,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37428 Qualigen Therapeutics, Inc. (Exact name

License Agreement with UCL Business Limited dated January 12, 2022

Exhibit 10.55 LICENCE AGREEMENT between UCL Business Limited and Qualigen Therapeutics, Inc. Dated: 13/01/2022 Ref: INDEX 1. Definitions 1 2. Grant of Rights 10 3. Know-how and other Confidential Information 15 4. Payments 17 5. Commercialisation 24 6. Access to Medicines and Ethical Licensing 27 7. Compliance with Laws 29 8. Intellectual Property 31 9. Warranties and Liability 33 10. Duration and

Second Amendment to Lease with Bond Ranch LP dated December 15, 2021

Exhibit 10.54 Second AMENDMENT TO LEASE THIS AMENDMENT TO LEASE is made and entered into as of December 15, 2021, by and between Bond Ranch LP, a California Limited Partnership (?Lessor?) and Qualigen, Inc., A Delaware Corporation (?Lessee?). WHEREAS, on or about December 7, 2021 a Lease was entered into by and between Lessor and Lessee relating to certain real property commonly known as (street a

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37428 Qualigen Therapeutics, Inc. (Exact name of registrant as spe

Subsidiaries of the Registrant

Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Qualigen, Inc. ? a Delaware corporation.

Executive Employment Agreement dated December 10, 2021 with Amy Broidrick

Exhibit 10.53 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (this ?Agreement?) is entered into effective as of December 10, 2021 (the ?Effective Date?), by and between Qualigen Therapeutics, Inc., a Delaware corporation with its principal office at 2042 Corte Del Nogal, Carlsbad, CA 92011 USA (the ?Company?), and Amy Broidrick (the ?Executive?), whose address is 1440 Valle Gra

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2022 Qualigen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-37428 26-3474527 (State or other jurisdiction of incorporation) (Commissi